StockWatch
·

Meghmani Finechem Ltd Q1 FY26 Results

EPIGRALQ1 FY26 Results
Filing
MetricValue (₹ Cr)vs Q4 FY25
Revenue606.543.4%
Total Income614.792.6%
Expenditure508.061.6%
PBT106.7318.6%
Net Profit160.6984.9%
OPM26.94%0.68pp
NPM26.14%12.37pp
EPS37.2585.0%
View full financials

Epigral Ltd Reports Q1 FY26 Revenue of ₹ 615 Crore, PAT at ₹ 160 Crore

02 Aug 2025 · 2 Aug 2025, 02:07 pm

Summary

Epigral Ltd, a leading integrated chemical manufacturer in India, announced its financial results for Q1 FY26. The company reported a revenue of ₹ 615 Crore, a decrease of 6% from Q1 FY25. Despite the drop in revenue, Epigral managed to maintain its EBITDA margin at 27%. The company's PAT stood at ₹ 160 Crore, including a decrease in deferred tax liability of ₹ 81 Cr. The Chairman and Managing Director, Mr. Maulik Patel, expressed optimism for H2FY26 and announced plans for a new chemistry project.

Key Highlights

  1. 1

    Q1FY26 Revenue stood at ₹ 615 Crore

  2. 2

    Plant utilization stood at 73%

  3. 3

    ROCE grew to 24% as on 30th June 2025

  4. 4

    Net Debt/EBITDA reduced to 0.6x as on 30th June 2025

  5. 5

    YoY Revenue dropped by 6% to ₹ 615 Crore

  6. 6

    EBITDA dropped by 7% to ₹ 163 Crore

  7. 7

    PAT stood at ₹ 160 Cr

  8. 8

    Epigral Capex plans are moving as per schedule

  9. 9

    CPVC Resin capacity will reach to 1,50,000 TPA

  10. 10

    Epichlorohydrin capacity will reach to 1,00,000 TPA

  11. 11

    Wind Solar Hybrid Power Plant capacity will reach to 38.14 MW

Management Comments

M

Mr. Maulik Patel

Q1FY26 quarter ended with slightly lower volume and drop in realizations, however we maintained our EBITDA margin of 27% on account of sustaining efficiency level and better product mix. We expect H2FY26 to be stronger compared to H1FY26. Revenue contribution from Derivatives and Specialty business stood at 50% and we expect this to further increase. Our capex projects of expanding CPVC and Epichlorohydrin capacity are moving as per schedule and are expected to be commissioned within the target timeline and budget. We are still left with a land parcel in the current complex for which we will announce a capex to further strengthen our integrated complex. We are working on the new chemistry at our new land parcel. This new chemistry project will be on similar lines of our earlier projects, i.e. import substitution products where demand is expected to grow in double digits and where we can generate good ROCE. We continue our journey to move forward in our direction of scalability with profitability, strengthening our integration and creating value for our stakeholders.

Informational and educational content only. Not investment advice.